INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Pulse Biosciences, Inc. (PLSE) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) investors concerning the Company’s possible violations of federal securities laws.

On February 8, 2022, Pulse announced that the U.S. Food and Drug Administration (“FDA”) concluded there was insufficient clinical evidence to support the Company’s 510(k) submission to expand the label for the CellFX System to treat sebaceous hyperplasia. Among other things, the FDA found “that the Company had not met the primary endpoints of the sebaceous hyperplasia FDA-approved IDE study.”

On this news, the Company’s stock price fell $3.74, or 34%, to close at $7.12 per share on February 8, 2022, thereby injuring investors.

If you purchased Pulse securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], toll-free at [phone], or by email to [e-mail], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.